# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks afte...
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Piper Sandler analyst Jason Bednar reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and lowers the price target ...
Citigroup analyst Ashiq Mubarack initiates coverage on Alpha Tau Medical (NASDAQ:DRTS) with a Buy rating and announces Price...
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no pr...
Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer th...